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Background: Failure to take medication reduces the effectiveness of treatment leading to increased morbidity and
mortality. We evaluated the efficacy of a consultation-based intervention to support objectively-assessed adherence
to oral glucose lowering medication (OGLM) compared to usual care among people with type 2 diabetes.
Methods: This was a parallel group randomised trial in adult patients with type 2 diabetes and HbA1c≥7.5% (58
mmol/mol), prescribed at least one OGLM. Participants were allocated to a clinic nurse delivered, innovative
consultation-based intervention to strengthen patient motivation to take OGLM regularly and support medicine
taking through action-plans, or to usual care. The primary outcome was the percentage of days on which the prescribed
dose of medication was taken, measured objectively over 12 weeks with an electronic medication-monitoring device
(TrackCap, Aardex, Switzerland). The primary analysis was intention-to-treat.
Results: 211 patients were randomised between July 1, 2006 and November 30, 2008 in 13 British general practices
(primary care clinics). Primary outcome data were available for 194 participants (91.9%). Mean (sd) percentage of adherent
days was 77.4% (26.3) in the intervention group and 69.0% (30.8) in standard care (mean difference between groups 8.4%,
95% confidence interval 0.2% to 16.7%, p=0.044). There was no significant adverse impact on functional status or
treatment satisfaction.
Conclusions: This well-specified, theory based intervention delivered in a single session of 30 min in primary care
increased objectively measured medication adherence, with no adverse effect on treatment satisfaction. These findings
justify a definitive trial of this approach to improving medication adherence over a longer period of time, with clinical and
cost-effectiveness outcomes to inform clinical practice.
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Between a third and a half of medicines prescribed for
long-term conditions are not taken as prescribed [1].
This applies equally to patients with type 2 diabetes who
are managed with multiple medications to control car-
diovascular risk factors and blood glucose [2]. Up to
37% of patients with diabetes have discontinued oral
hypoglycaemic drugs within one year of initiating treat-
ment [3], with adherence to medication falling as dosage
frequency rises [4]. For those who persist with therapy,
it is estimated that about 70-80% of doses are taken as
prescribed [5].
Failure to take medication reduces the effectiveness of
the treatment, and wastes healthcare resources in pre-
scribed medicines not taken, extra consultations, refer-
rals, investigations and hospital admissions [6,7]. The
availability of an effective consultation-based interven-
tion to support patients with long-term, progressive dis-
orders in taking their medication regularly would make
a major contribution to human health.
A variety of approaches to help patients take their medi-
cation regularly have been tested for efficacy [8]. However,
there are only a few rigorous trials, and these suggest that
interventions with multiple components are most effective
in improving clinical outcomes [8]. A greater focus on the
determinants of non-adherence may provide a basis for
improved effectiveness, as interventions should address
the principal causes of sub-optimal adherence. Since
causes are many and vary between individuals, the inter-
vention may need to be tailored to the individual.
The majority of studies have used measures of adher-
ence that are imprecise, often relying on self-report [8].
This can lead to biased estimation of intervention
effects, both within and between patient groups. Elec-
tronic measurement of adherence is increasingly used
in intervention studies, but there few trials of its use
among patients with type 2 diabetes have used it to date.
We have therefore drawn on psychological evidence and
theory about hypothesised causes of non-adherence relat-
ing to weak motivation (intentional non-adherence) and
forgetting (non-intentional non-adherence) [9], to develop
a nurse-led consultation-based intervention (the “Support
and Advice for Medication Study”; SAMS) targeting these
hypothesised determinants through elicitation of personal
beliefs. The intervention aims to increase patients’ motiv-
ation to take their tablets regularly by reinforcing positive
beliefs and facilitating problem-solving around negative
beliefs and to help patients translate motivation into ac-
tion by asking them to form and write down specific ac-
tion plans [10-12]. Both components are delivered in a
single, brief intervention, although, if effective, future work
could explore delivery over a longer period of time. We
evaluated this new intervention in an explanatory rando-
mised controlled trial to establish the short-term efficacyof the intervention on tablet taking behaviour and to in-
form estimates of the sample size for a pragmatic and de-
finitive trial with glycaemic control as the outcome. The
trial was carried out in a primary care setting among
adults with type 2 diabetes taking oral glucose lowering
medication (OGLM), with electronic measurement of
medication taking.Methods
Trial design
This trial formed part of a programme of work to evalu-
ate the efficacy of a new intervention, and obtain infor-
mation to refine its delivery and determine parameters
for future trial evaluation. We used a parallel group trial
design to evaluate a two-component intervention target-
ing motivation and using action planning in comparison
with a control “standard care” intervention (Figure 1).
An unbalanced (3:2) randomisation was used to provide
more data from patients exposed to the new interven-
tion, with little loss of power. The trial was carried out
in weeks 9 to 20 of a 20-week study in which there was
an initial, randomised evaluation of the impact of elec-
tronic medication measurement on adherence. In the
initial phase of this study (weeks 1 to 8), patients were
randomised to test the extent to which prior exposure to
use of an electronic medication container might affect
the results of the subsequent trial. Randomisation to the
intervention and standard care groups of the efficacy
trial took place at week 9 (see diagram).
The trial statistician randomly allocated patients inde-
pendently of trial co-ordination and intervention deliv-
ery teams. A partial minimisation procedure was used to
dynamically adjust randomisation probabilities to bal-
ance the baseline stratification variables. These included
self-reported adherence, the baseline allocation to use or
non-use of the electronic medicines measure and the
baseline HbA1c. The London multi-centre research
ethics committee reviewed and approved the protocol
(06/MRE02/3).Setting and patients
Patients were recruited from 13 general practices (pri-
mary care clinics) in Oxfordshire, Buckinghamshire, Suf-
folk, Essex and Huntingdonshire (UK). Patients were
eligible for inclusion if aged 18 years or over with type 2
diabetes of at least three months duration, able to give
informed consent, currently taking any oral glucose-
lowering agent and with a HbA1c ≥7.5% (58mmol/mol).
Patients were not excluded if taking insulin. Those
approached were deemed by their general practitioner to
be appropriate for tight glycaemic control and independ-
ent in medication taking.
Participating practices n=13
Total Patient list n=124176
Loss to follow up
n=5
People with type 2 diabetes
n=3575
Total eligible for mailing=797
Excluded at recruitment
2778 (77%)
(figures estimated from practice records)
108 (4%) diagnosed <3 months
499 (18%) diet only)
1716 (62%) HbA1c <7.5%
66 (2%) co morbidity
389 (14%) unable to comply with protocol
(includes 4<18 years)
Allocated intervention
n=126
Positive response
273 (34%)
Recruited
n=226
Randomized 3:2 to intervention /
standard care
n=211 (126/85)
Excluded at telephone contact
47 (17%)
(figures estimated from practice records)
17 (36%) HbA1c <7.5%
5 (11%) diet only)
2 (4%) co morbidity
11 (23%) unable to comply with protocol
12 (26%) Unable to contact
Allocated standard care
n=85
Loss to follow up
n=1
Received intervention
n=119
Received standard care
n=82
Follow up intervention
n=114
Follow up standard care
n=81
Withdrawn between
randomization and
attending eight week
visit
n=7
Withdrawn between
randomization and
attending eight week
visit
n=3
Withdrawn prior to
randomization at eight
weeks
N=15
Data collected on non
responders
413/524 (78%)
9/13 practices
Figure 1 Trial Profile.
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The primary outcome was the percentage of days over a
twelve-week period on which the correct number of doses
of main glucose lowering medication was taken each day
as prescribed. It was measured using a validated measuring
device [13], a container with a lid incorporating an elec-
tronic device that recorded the occurrence and timing of
opening (TrackCap, Aardex, Zurich, Switzerland). A single
treatment was tracked for each patient during the period
of the trial, with metformin the preferred medication.
Secondary outcomes included: functional status mea-
sured with the 12-item Short Form Medical Outcomes
Study health survey questionnaire (SF-12) [14], treatment
satisfaction measured with the Diabetes Treatment Satis-
faction Questionnaire (DTSQ) [15], satisfaction with com-
munication with the nurse delivering the intervention and
the Medication Adherence Report Scale (MARS) [16].
The MARS scale assesses adherence to medication with afive-item self report scale each with item responses scored
on a five point scale. Scores are summed to give a score
ranging from 5 to 25 with a higher score indicating higher
levels of reported adherence. In addition, the number of
medications taken was recorded and HbA1c was measured
in a central laboratory. The measures are fully described
in the trial protocol [10].
Trial intervention
Eight weeks after recruitment, patients were invited to
the intervention visit to record and review their medica-
tion and randomised to either an intervention to support
medication adherence or a standard care visit in which
trial measurements were taken. The intervention had
been developed and piloted after a detailed study to
identify beliefs held by patients about diabetes and medi-
cation taking [17]. The intervention was delivered by a
clinic nurse in each practice.
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vided initial training for the clinic nurses at a day meet-
ing supported by a detailed manual [10]. The nurses
used protocols to standardise delivery of both the inter-
vention and the standard care visit. The psychologist
and intervention facilitators provided coaching and feed-
back to the nurses to ensure that the intervention and
standard care were delivered as planned and to ensure
intervention fidelity. This addressed possible sources of
contamination in intervention delivery including the
need to avoid (i) delivering the intervention to standard
care patients, (ii) discussing motivational strategies and
action planning with other members of the primary care
team and (iii) using intervention strategies not specified
in the protocol. Delivery of protocols was monitored by
formal assessment of audio-taped consultations with all
intervention participants and a sample of standard care
participants [10].
In the first, motivational component of the intervention,
the nurse elicited patients` beliefs relevant to their intention
to take medication regularly as prescribed using a series of
questions based on the Theory of Planned Behaviour [11].
These included perceived benefits and harms of taking
medicines, views of other people who were important to
them and factors that may facilitate or inhibit taking medi-
cines regularly as prescribed. Positive beliefs were rein-
forced verbally and non-verbally through provision of
tailored information and problem solving was facilitated
around negative beliefs. In the second, action planning
component, the nurse asked patients to generate and write
down the exact circumstances in which they would take
their medication (using an “if-then” formulation to elicit
where, when and how this would occur) [12]. In the stand-
ard care visit, delivered by the same clinic nurses, none of
the above techniques were applied.
Study procedures
The clinic nurse identified eligible patients registered
with the practice. Eligible patients were sent a letter
from the practice giving details of the trial, and a ques-
tionnaire asking about basic demographics, medication
regimen, medication adherence and beliefs about taking
diabetes medicines. Responders were telephoned by the
clinic nurse to arrange a recruitment visit to the full
twenty week study period. Patients eligible and willing to
take part were randomly allocated in advance of their re-
cruitment visit to receive their medication in a medica-
tion monitoring device or in standard packaging.
At the 40-min trial recruitment visit with the clinic
nurse, patients gave informed consent, including consent
for tape-recording interviews for the purposes of training
and assessment of fidelity of intervention delivery. Clinical
data were collected, blood was taken, and questionnaires
completed. For those patients allocated to the electronicmedication-monitoring device, its use was explained,
and the practice dispenser or pharmacist dispensed the
patient’s usual prescription for metformin or alternative
oral glucose lowering agent in the device. For those allo-
cated to standard packaging, the practice dispenser or
pharmacist provided medication in standard blister-packs.
A follow-up and intervention visit was arranged after eight
weeks.
In advance of the intervention visit, patients were sent a
questionnaire from the coordinating centre. Also in ad-
vance of the intervention visit, patients were centrally ran-
domised to the intervention or standard care to allow the
clinic nurse to prepare to follow the allocated intervention
schedule. At the visit, patients allocated to the intervention
took part in a consultation, intended to last 50 min, with
the clinic nurse that included the intervention (approxi-
mately 30 min) and data collection (approximately 20 min).
The standard care visit lasted approximately 20 min during
which study data were collected. At the intervention visit,
blood samples were taken from all patients and enquiries
were made about any possible adverse events including
hypoglycaemia. All patients were dispensed their usual pre-
scription for metformin or alternative oral glucose lowering
agent in a medication monitoring device. A postal question-
naire was completed one week after the intervention visit.
Final follow up for all patients at 20 weeks involved a visit
to the clinic nurse and included retrieval of the medication
monitoring devices, a blood sample for measurement of
HbA1c and a final questionnaire.
Resource use data were collected on the time taken by
clinic nurses to deliver the intervention and collect clin-
ical samples at the intervention visit (preparation time,
duration of visit and other input) and, in the case of
standard care, the time taken to collect clinical informa-
tion. Data were also collected on the time taken by inter-
vention facilitators to train the nurses and to provide
feedback.
Analysis methods
The trial was planned to follow up 200 patients, provid-
ing 80% power at the 5% significance level to detect a
difference in means between randomised groups of 5%
(1.5 days per month difference) in the percentage of
days on which the correct number of doses was
recorded as being taken. This was based on an estimate
of the standard deviation of this measure of 13.5% in a
pilot study for the trial conducted in 2001 in Newmarket,
Cambridgeshire [10].
Analysis was by intention to treat and continuous out-
comes were analysed adjusting for their corresponding
baseline value, where this was measured, to improve pre-
cision. Where applicable, the missing indicator method
was used [18], so that patients with a missing baseline
value could be incorporated. Laboratory measurements
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treatment allocation.
The primary outcome was adherence, defined as the per-
centage of days over 12 weeks on which the correct num-
ber of doses was taken. It was calculated from medication
monitoring data recorded from the day after the interven-
tion visit (week 9) following randomisation through to the
day of the last visit (week 20). Mean adherence was com-
pared between the intervention and control groups using
the non-parametric percentile bootstrap method to derive
the difference in means with a 95% confidence interval.
Subgroup analyses were carried out to explore the im-
pact on the intervention effect of pre-specified baseline
subgroup variables: HbA1c, age, gender, number of medi-
cations, self-reported adherence, and prior randomization
to the electronic medication-monitoring device. These
were assessed by testing the effect on the primary out-
come of the interaction between each subgroup variable
and the randomised group. For this purpose, continuous
subgroup variables were dichotomised at the median. An
additional analysis was carried out to explore the extent to
which prior use of the medication-monitoring device
affected nine to 20 week adherence.Table 1 Baseline characteristics of trial participants
Intervention arm
Socio demographic N=126
% male (N) 61.9% (78)
Age (years) 62.5 (11.0)
IMD Deprivation rank (0-100) 10.2 (6.4)
Health-related
SF12 Physical [3] (norm 50 43.3 (11.2)
range 0-100)
SF12 Mental [3] (norm 50 48.0 (10.6)
range 0-100)
Duration of diabetes (years) 6.7 (4.8)
Weight (kg) 97.4 (21.7)
Systolic blood pressure (mmHg) 137.4 (16.2)
Diastolic blood pressure (mmHg) 78.3 (8.9)
HbA1c (%) [1] 8.37 (1.25)
HbA1c (mmol/mol) 68.0 (2.7
Medication-related
% treated with metformin (N) [4] 86.7% (104)
Metformin daily dose (mg) * [4] 1450 (795)
Total number of medications taken/day 5.7 (2.4)
Adherence (MARS) [2] (range 5-25) 23.6 (2.3)
Values are mean (SD) unless otherwise stated: missing data: [1] 17; [2] 23; [3] 2; [4]
* for those treated with metformin.
MARS Medication Adherence Report Scale.Results
In the 13 participating practices, 797 registered patients
with type 2 diabetes potentially meeting the inclusion
criteria were identified, of whom 273 responded as eli-
gible, and 211 were confirmed as eligible on assessment
and randomised with 92% follow up (Figure 1). Recruit-
ment began in July 2006 and follow up was completed
by November 2008. Trial participants in intervention
and standard care groups were similar, in their early 60s
with diabetes for less than 10 years and taking on aver-
age 6 medications daily and reporting a score of ≥24 on
the MARS scale indicating high medication adherence.
A slightly greater proportion of men were allocated to
standard care (Table 1). In 9 of the 13 trial practices
comparison of trial participants and non-responders
suggested that trial participants had a shorter duration
of diabetes and were more likely to be prescribed met-
formin (Table 2).
Patients allocated to the intervention took their prescribed
number of doses of medication on a significantly higher per-
centage of days compared to the standard care group
(Table 3). The mean difference between groups in percent-
age of days that the correct number of doses of medicationStandard Care arm All participants
N=85 N=211
70.6% (60) 65.4% (138)
64.1 (10.3) 63.2 (10.7)
10.4 (6.8) 10.3 (6.8)
45.5 (10.3) 44.2 (10.9)
50.0 (9.6) 48.8 (10.2)
6.9 (5.3) 6.8 (5.0)
94.5 (19.6) 96.2 (20.9)
136.2 (15.9) 136.9 (16.0)
78.1 (9.1) 78.2 (9.0)
8.28 (1.22) 8.33 (1.24)
67.0 (2.4) 67.5 (2.6)
87.9% (73) 87.2% (177)
1525 (780) 1480 (788)
5.9 (2.6) 5.8 (2.5)
23.6 (2.8) 23.6 (2.5)
8.
Table 2 Comparison of non-responders with trial
participants*
Participants* Non-Responders
Mean (SD) Mean (SD)
N= 133* N = 413
% male (N) 65.4 (87) 62.7 (259)
Age (years) 62.7 (10.7) 64.7 (12.8)
HbA1c (%) 8.3 (1.2) [1] 8.7 (1.5) [2]
HbA1c (mmol/mol) 67 (13) 72 (16)
Duration of diabetes (years) 6.5 (4.9) 8.1 (7.1) [3] **
% prescribed metformin (N) 87.8 (115) [4] 76.0 (307) [5] **
Values are mean (SD) unless otherwise stated.
Missing data: [1]n = 9; [2]n = 1; [3]n = 5; [4]n = 2; [5]n = 5.
*Those participants from the nine practices in which non-responder data were
collected.
** P< 0.05.
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0.2% to 16.7%, p=0.044). No patients were identified as
stopping their medication during the period of twelve weeks.
There were no significant differences between groups for
secondary outcomes including self report medication
adherence (MARS), SF-12, diabetes treatment satisfaction,
HbA1c, satisfaction with communication with the nurse, or
hypoglycaemia (Table 3).
There were no significant interactions to indicate that
the effect of the intervention on the medication adherence
outcome varied greatly by gender, number of medications,
self-reported adherence (Table 4). However, taking into ac-
count the reported confidence intervals, the intervention
effect may have been larger in those with better glycaemic
control (p=0.07), older age (p=0.19) and higher self-
reported adherence at baseline (p=0.11). There was noTable 3 Outcomes twelve weeks after randomisation to interv
Intervention arm
Baseline Final visit
Primary outcome
Days correct dose taken (SD) (%)* - 77.4 (26.3)a
Secondary outcomes
SF12 Physical (SD) † 43.3 (11.2) r 44.6 (11.1)
SF12 Mental (SD) † 48.0 (10.6) 49.5 (10.4)
Diabetes treatment satisfaction (SD) - 30.6 (5.4) c
HbA1c % (SD)
† 8.34 (1.26) k 8.34 (1.24)
HbA1c mmol/l (SD) 67.7 (13.8) 67.7 (13.6)
Medication-related
MARS Self report adherence (SD) † 23.6 (2.3) d 23.6 (2.6) e
Satisfaction with communication (median, IQR)** 4 (2,5)
% reporting hypoglycaemia (N)*** 1.6% (2)
Values are mean (SD) unless otherwise stated. Missing values: a = 13, b = 4, c = 17, d
* - Estimate of intervention effect adjusted for baseline where available and 95% co
method with 50,000 replications. †= In the analysis of the final visit measure adjust
method is used. ** p value from Mann–Whitney test., *** p value from Fisher’s exaceffect of prior allocation of patients to the electronic
medication-monitoring device in the first phase of the
study with a mean (95% confidence intervals) difference of
6.0 (-10.5, 22.7) in percentage of days of medication not
taken between groups (p=0.48) (Table 4). In addition there
was not an effect of prior allocation to the electronic medi-
cation monitoring device on overall nine to 20 week adher-
ence (p=0.84).
The mean total time (95% confidence interval) spent
in delivering the intervention and associated clinical care
data collection was 74 min (68 to 79) for the interven-
tion group and 42 min (39 to 47) for the standard care
group; a mean difference of 31 min (95% confidence
interval 25 to 37). Intervention facilitators spent, on
average, 2.3 h per patient listening to tape recordings,
training nurses, and providing feedback in the interven-
tion group, compared with 1.2 h in standard care.
Discussion
A theoretically based, single session intervention delivered
to patients with type 2 diabetes in primary care consulta-
tions by clinic nurses was effective in improving object-
ively measured glucose lowering medication adherence
compared with standard care. The effect was seen consist-
ently over the 12 weeks of the study. The intervention had
no adverse effect on measures of functional status, satis-
faction, communication or hypoglycaemia. There was no
effect on glycaemia measured by HbA1c, but the power
and time frame of our trial were not designed to test for
this effect.
This study addressed key weaknesses in previous studies
that have limited the quality of the evidence concerning
medication adherence. The most effective interventions toention or standard care
Standard care arm Intervention effect (95% C.I) P-value
Baseline Final visit
69.0 (30.8)b 8.4 (0.2, 16.7) c 0.044
c 45.5 (10.3) r 46.3 (9.0) l -0.7 (-2.7, 1.4) s 0.52
c 50.0 (9.63) t 52.6 (8.8)l -1.6 (-3.9, 0.6) s 0.15
- 31.3 (4.6) f -0.7 (-2.2, 0.7) u 0.32
k 8.29 (1.23) l 8.21 (1.32) f 0.06 (-0.19, 0.32) m 0.64
67.1(13.4) 66.2 (14.4) 0.7 (- 2.1, 3.5)
23.6 (2.8) f 24.1 (1.6) g -0.4 (-1.0, 0.2) h 0.20
4 (2,5) 0.13
0,0 (0) 0.52*
= 15, e = 27, f = 8, g = 12, h = 39, k = 16, l = 9, m= 24, r = 1, s = 26, t = 2, u = 25.
nfidence interval derived from the non-parametric bootstrap percentile
ing for a baseline that has occasional missing data, the missing indicator
t test. MARS Medication Adherence Report Scale.
Table 4 Subgroup analysis of the intervention effect on the percentage of days adherence to prescribed medication
Sub-group variable Sub-group category
(L = Low or H=High)
N per sub
group
Intervention
arm
Standard
care arm
Intervention-
Control (SE)*
Difference (H-L)
(95% C.I.)
P
interaction
HbA1c % (mmol/mol) 7.5 – 7.9 (58-63) 85 80.4 (24.5) 62.6 (34.2) 17.7 (6.4)
8.0 - 12.4 (64-112) 108 74.8 (27.7) 72.8 (27.8) 2.0 (5.3) -15.8 (-32.9, 1.2) 0.07
Age (years) 37 – 64 94 75.0 (25.61) 72.3 (27.3) 2.7 (5.6)
65 and over 100 80.0 (27.1) 66.4 (33.2) 13.5 (6.0) 10.8 (-5.4, 27.2) 0.19
Total number of medications 0 – 5 89 80.2 (23.3) 73.0 (27.0) 7.2 (5.3)
6 and over 105 75.1 (28.5) 65 .2 (33.7) 10.0 (6.1) 2.8 (-13.5, 19.1) 0.74
Self reported adherence at
baseline
0-23 102 75.0 (26.4) 70.9 (27.2) 4.1 (5.5)
24 or 25 70 85.9 (21.3) 68.0 (33.9) 17.9 (6.8) 13.8 (-3.2, 30.0) 0.11
Prior randomisation to medication
monitoring device
No 102 76.6 (28.7) 71.0 (29.3) 5.6 (5.8)
Yes 92 78.2 (23.7) 66.65 (32.6) 11.6 (5.9) 6.0 (-10.5, 22.7) 0.48
Gender Male 127 77.0 (28.3) 66.4 (31.5) 10.6 (5.3)
Female 67 78.0 (22.9) 74.8 (28.8) 3.3 (6.4) -7.3 (-24.3, 9.6) 0.39
Effect estimates, confidence intervals and p-values from non-parametric bootstrap percentile method (50,000 replications).
* Estimated intervention effects are positive within each subgroup.
Farmer et al. BMC Family Practice 2012, 13:30 Page 7 of 9
http://www.biomedcentral.com/1471-2296/13/30improve medication adherence and clinical outcomes have
been complex, multi-component and intensive, but few
studies have been designed to allow exploration of the rea-
sons for success or failure of interventions and their deliv-
ery [19]. Target groups have often been poorly defined
and characterised and trial participants also tend to be un-
usually adherent, limiting discovery of effects that would
be important in general populations [20-22]. The most
commonly used measures are self report and these are
often associated with larger effects than objective meas-
urement [23,24]. Trial designs themselves have often been
weak with lack of attention to central randomisation and
sources of bias. Not surprisingly, previous studies in this
field have shown inconsistent effects.
We addressed these issues in the following ways. We
developed the intervention systematically from psycho-
logical evidence and theory [25]. It is predicated on
addressing weak motivation associated with ambivalence
to medication taking [26], and the gap between intention
and action that may be bridged by making specific
action plans [11,12]. We ensured the intervention was
feasible to deliver in a health service context and addressed
quality assurance. Nurses were trained to deliver the inter-
vention in workshops using scripts and feedback, and con-
sultations were audio-taped to assure delivery as planned
and to support a consistent approach to delivery across
nurses over time.
We also identified a patient group with the potential
to benefit from improving their adherence to medica-
tion. They comprised a well characterised population
which reflected the kind of patients with diabetes seen
in primary care every day: in their sixties, with estab-
lished diabetes of seven years mean duration, andprescribed an average six of medications daily, including
metformin, without having reached optimum glycaemic
control. In addition we obtained an acceptable rate of
participation from eligible patients, and were able to
demonstrate that the characteristics of these individuals
were similar to the wider population from which they
were recruited.
We measured the primary outcome objectively using a
validated electronic medication monitor [13] that allows a
day-by-day description of adherence as well as providing
summary measures. In an initial, randomised evaluation of
the impact of electronic medication measurement on adher-
ence we found that prior use of an electronic medication-
monitoring device had no statistically significant effect either
on adherence or in modifying the intervention effect on ad-
herence for the primary outcome. The study design was
rigorous with central randomisation and blinding of group
allocation from those assessing outcome. Randomly allo-
cated groups were well matched on the measured variables.
There are number of limitations to this study. The par-
ticipation rate was not high, although attempts were made
to mitigate this by anonymised collection of data on non-
participants. We restricted our intervention to glucose
lowering medication and excluded those in whom tight
glucose control was inappropriate, although support for
taking other medications might be appropriate for this
group of patients. Detailed work was undertaken to min-
imise the possibility of contamination between interven-
tion and usual care groups, although any failure of the
procedures put in place would reduce the size of effect
observed. Self reported adherence, as measured by the
MARS self-report questionnaire, did not differ between
intervention and usual care groups. MARS attempts to
Farmer et al. BMC Family Practice 2012, 13:30 Page 8 of 9
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altering, stopping, missing or taking less medication than
prescribed. Moreover, estimates of adherence were close
to maximal in both groups as has been found elsewhere
[17,27]. Thus, while the MARS results did not confirm
our principal outcome of electronic monitoring, it may be
because the latter is measuring a different component of
adherence, being more sensitive to unconscious non-ad-
herence, and also that it is less constrained by ceiling
effects. Self-report measures, when used in trials may also
be difficult to interpret, as they are more susceptible to
outcome preference bias.
Our aim in this short-term explanatory study was to es-
timate the efficacy of the intervention on the behaviour of
taking medication and the trial was therefore not powered
to evaluate glycaemic effects. However, we anticipated that
with a large effect on tablet taking, we might see some in-
dication of an effect on HbA1c. Efficacy studies with simi-
lar time periods and doses of metformin (1500g per day)
have demonstrated improvements in HbA1c of around
1.5% compared with placebo among patients with very
poorly controlled diabetes at baseline [28], but smaller
effects among patients under better control [29]. However,
the impact of the improved adherence of about one week
over the three month period in our intervention group
was not sufficient to alter overall glycaemia.
Conclusions
We have demonstrated that a well-specified and repro-
ducible consultation-based intervention delivered in a
single session by clinic nurses in primary care can in-
crease objectively measured medication adherence with
no adverse effect on treatment satisfaction. Application
of this approach offers the potential for reducing the
burden of disease in diabetes managed by long-term
medication. A larger pragmatic trial, with further devel-
opment of intervention components, designed to sustain
effect, with longer follow up, and powered to evaluate
the effect of the intervention on clinical outcomes is
justified.
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